Trial Profile
Pharmacokinetics of Micafungin (Mycamin) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Micafungin (Primary)
- Indications Aspergillosis
- Focus Pharmacokinetics
- Acronyms MATADOR
- 22 Aug 2018 Results published in the Journal of Antimicrobial Chemotherapy
- 15 Sep 2016 Status changed from recruiting to completed.
- 29 Oct 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.